Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04144569
PHASE2
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Sponsor: Yongchang Zhang
View on ClinicalTrials.gov
Summary
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Official title: the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-01-30
Completion Date
2024-12-31
Last Updated
2024-09-19
Healthy Volunteers
No
Interventions
DRUG
PD-1 Combined With Pyrotinib
PD-1 Combined With Pyrotinib
Locations (1)
Hunan Provincal Tumor Hospital
Changsha, Hunan, China